- Home
- CCCC vs AOMR Comparison
CCCC vs AOMR Comparison
Compare CCCC & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- AOMR
- Stock Information
- Founded
- CCCC 2015
- AOMR 2018
- Country
- CCCC United States
- AOMR United States
- Employees
- CCCC N/A
- AOMR N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- AOMR Real Estate Investment Trusts
- Sector
- CCCC Health Care
- AOMR Real Estate
- Exchange
- CCCC Nasdaq
- AOMR Nasdaq
- Market Cap
- CCCC 242.3M
- AOMR 224.3M
- IPO Year
- CCCC 2020
- AOMR 2021
- Fundamental
- Price
- CCCC $2.44
- AOMR $8.29
- Analyst Decision
- CCCC Strong Buy
- AOMR Strong Buy
- Analyst Count
- CCCC 4
- AOMR 6
- Target Price
- CCCC $8.50
- AOMR $11.13
- AVG Volume (30 Days)
- CCCC 1.5M
- AOMR 149.5K
- Earning Date
- CCCC 11-06-2025
- AOMR 11-06-2025
- Dividend Yield
- CCCC N/A
- AOMR 15.65%
- EPS Growth
- CCCC N/A
- AOMR N/A
- EPS
- CCCC N/A
- AOMR 0.73
- Revenue
- CCCC $30,108,000.00
- AOMR $34,705,000.00
- Revenue This Year
- CCCC N/A
- AOMR N/A
- Revenue Next Year
- CCCC N/A
- AOMR $15.19
- P/E Ratio
- CCCC N/A
- AOMR $11.34
- Revenue Growth
- CCCC N/A
- AOMR N/A
- 52 Week Low
- CCCC $1.09
- AOMR $7.36
- 52 Week High
- CCCC $5.10
- AOMR $10.88
- Technical
- Relative Strength Index (RSI)
- CCCC 49.92
- AOMR 30.08
- Support Level
- CCCC $2.39
- AOMR $8.83
- Resistance Level
- CCCC $2.63
- AOMR $9.05
- Average True Range (ATR)
- CCCC 0.16
- AOMR 0.24
- MACD
- CCCC -0.00
- AOMR -0.07
- Stochastic Oscillator
- CCCC 57.63
- AOMR 9.89
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.